资源类型：
会议/期刊
收录情况：
◇ SCIE
◇ CPCI(ISTP)
文章类型：
会议摘要
作者：
Yang, Xubin[1]
*
;
Xu, Wen[1]
;
Zhu, Dalong[2]
;
Sun Zilin[3]
;
Guo, Lixin[4]
;
Yang, Tao[5]
;
Wu, Ge[6]
;
Shi, Lixin[7]
;
Li, Qifu[8]
;
Qiu, Lin[9]
;
Li, Qiang[10]
;
Guo, Xiaohui[11]
;
Luo, Zuojie[12]
;
Lu, Juming[13]
;
Shan, Zhongyan[14]
;
Yang, Wenying[15]
;
Ji, Qiuhe[16]
;
Yan, Li[17]
;
Li, Hong[18]
;
Yu, Xuefeng[19]
;
Li, Shaoqing[20]
;
Zhou, Zhiguang[21,22]
;
Lv, Xiaofeng[23]
;
Liang, Zhen[24]
;
Lin, Shaoda[25]
;
Zeng, Longyi[1]
;
Yan, Jinhua[1]
;
Ji, Linong[26]
;
Weng, Jianping[1]
;
单位：
[1]Sun Yat Sen Univ, Affiliated Hosp 3, Guangdong Prov Key Lab Diabetol, Dept Endocrinol & Metab, Guangzhou, Guangdong, Peoples R China
中山大学附属第三医院
[2]Nanjing Univ, Sch Med, Drum Tower Hosp, Dept Endocrinol, Nanjing, Jiangsu, Peoples R China
[3]Southeast Univ, Sch Med, Inst Diabet, Dept Endocrinol,Zhongda Hosp, Nanjing, Jiangsu, Peoples R China
[4]Beijing Hosp, Minist Publ Hlth, Dept Endocrinol, Beijing, Peoples R China
[5]Nanjing Med Univ, Affiliated Hosp 1, Dept Endocrinol, Nanjing, Jiangsu, Peoples R China
江苏省人民医院
[6]Guangdong Med Coll, Affiliated Hosp, Dept Endocrinol, Zhanjiang, Peoples R China
[7]Guiyang Med Coll, Affiliated Hosp, Dept Endocrinol, Guiyang, Guizhou, Peoples R China
[8]Chongqing Med Univ, Affiliated Hosp 1, Dept Endocrinol, Chongqing, Peoples R China
重庆医科大学附属第一医院
[9]Inner Mongolia Med Univ, Affiliated Hosp, Dept Endocrinol, Hohhot, Peoples R China
[10]Harbin Med Univ, Affiliated Hosp 2, Dept Endocrinol, Harbin, Peoples R China
[11]Peking Univ, Hosp 1, Dept Endocrinol, Beijing, Peoples R China
[12]Guangxi Med Univ, Affiliated Hosp 1, Dept Endocrinol, Nanning, Peoples R China
[13]Chinese Peoples Liberat Army Gen Hosp, Dept Endocrinol, Beijing, Peoples R China
[14]China Med Univ, Affiliated Hosp 1, Dept Endocrinol, Shenyang, Peoples R China
[15]China Japan Friendship Hosp, Dept Endocrinol, Beijing, Peoples R China
[16]Fourth Mil Med Univ, Xijing Hosp, Dept Endocrinol & Metab, Xian, Peoples R China
[17]Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Endocrinol, Guangzhou, Guangdong, Peoples R China
中山大学附属第二医院
[18]Kunming Med Univ, Affiliated Hosp 1, Dept Endocrinol, Kunming, Peoples R China
昆明医科大学附属第一医院
[19]Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Endocrinol, Wuhan, Peoples R China
内科学系
内分泌内科
华中科技大学同济医学院附属同济医院
[20]Qingyuan Peoples Hosp, Dept Endocrinol, Qingyuan, Peoples R China
[21]Cent South Univ, Xiangya Hosp 2, Inst Metab & Endocrinol, Diabet Ctr, Changsha, Hunan, Peoples R China
[22]Cent South Univ, Key Lab Diabet Immunol, Minist Educ, Changsha, Hunan, Peoples R China
[23]Gen Hosp Beijing Mil Region, Dept Endocrinol, Beijing, Peoples R China
[24]Shenzhen Univ, Dept Endocrinol, Affiliated Hosp 1, Shenzhen, Peoples R China
[25]Shantou Univ, Affiliated Hosp 1, Dept Endocrinol, Med Coll, Shantou, Peoples R China
[26]Peking Univ, Peoples Hosp, Dept Endocrinol, Beijing, Peoples R China
出处：
DIABETES-METABOLISM RESEARCH AND REVIEWS.2016,32(SUPP 2):17-18.
ISSN：
1520-7552
关键词：
Adipokines
hypoglycemic agents
diabetes mellitus
type 2
WOS：
WOS:000386961400028
中科院(CAS)分区：
出版当年[2015]版：
大类
|
3 区
医学
小类
|
3 区
内分泌学与代谢
最新[2025]版：
大类
|
3 区
医学
小类
|
3 区
内分泌学与代谢
JCR分区：
出版当年[2014]版：
Q2
ENDOCRINOLOGY & METABOLISM
最新[2023]版：
Q1
ENDOCRINOLOGY & METABOLISM
影响因子：
4.6
最新[2023版]
6.4
最新五年平均
3.553
出版当年[2014版]
3.416
出版当年五年平均
3.593
出版前一年[2013版]
3.064
出版后一年[2015版]
第一作者：
Yang, Xubin
第一作者单位：
[1]Sun Yat Sen Univ, Affiliated Hosp 3, Guangdong Prov Key Lab Diabetol, Dept Endocrinol & Metab, Guangzhou, Guangdong, Peoples R China
推荐引用方式(GB/T 7714)：
Yang Xubin,Xu Wen,Zhu Dalong,et al.Changes in adipokines in newly diagnosed type 2 diabetes patients treated with exenatide, insulin or pioglitazone[J].DIABETES-METABOLISM RESEARCH AND REVIEWS.2016,32(SUPP 2):17-18.
APA：
Yang, Xubin,Xu, Wen,Zhu, Dalong,Sun Zilin,Guo, Lixin...&Weng, Jianping.(2016).Changes in adipokines in newly diagnosed type 2 diabetes patients treated with exenatide, insulin or pioglitazone.DIABETES-METABOLISM RESEARCH AND REVIEWS,32,(SUPP 2)
MLA：
Yang, Xubin,et al."Changes in adipokines in newly diagnosed type 2 diabetes patients treated with exenatide, insulin or pioglitazone".DIABETES-METABOLISM RESEARCH AND REVIEWS 32..SUPP 2(2016):17-18
